Elevra Lithium Limited reported a loss from operations of AU$384.3 million for the fiscal year ended June 30, 2025, compared to a loss of AU$119.1 million for the year ended June 30, 2024. The increase in loss was primarily due to operating costs at North American Lithium and an impairment and write down of non-financial assets, partially offset by higher revenue from the sale of spodumene concentrate. Net financial expense for the fiscal year ended June 30, 2025 was AU$0.4 million, compared to net financial income of AU$3.6 million in the previous year. This change was mainly due to a decrease in interest income on cash and cash equivalents, which was AU$4.3 million in 2025 compared to AU$7.7 million in 2024, and an increase in interest on preference shares. As of June 30, 2025, Elevra reported cash and cash equivalents of AU$72.0 million, of which AU$0.1 million was restricted. The primary sources of liquidity were equity financing, revenue from operations, and proceeds from non-controlling interests, which were used for operational and capital expenditures in Canada and Australia. Elevra's business performance remains closely linked to trends in the global lithium market, driven by demand for lithium-ion batteries and electric vehicles. The company's research and development costs were not material, and there were no patents or licenses material to its business or profitability during the period.